Does anastrozole cause hair loss? Yes — alopecia is listed as a 'common' side effect in the MHRA-approved Summary of Product Characteristics for anastrozole, affecting an estimated 1 in 100 to 1 in 10 users. Anastrozole is an aromatase inhibitor widely prescribed across the UK for hormone receptor-positive breast cancer in postmenopausal women. By significantly reducing oestrogen levels, it can disrupt the normal hair growth cycle, leading to diffuse thinning rather than the complete hair loss associated with chemotherapy. This article explains the evidence, how common it is, and what support is available.

Anastrozole and Hair Loss: What the Evidence Shows

Anastrozole causes hair loss in some users — the MHRA-approved SmPC classifies alopecia as a 'common' side effect, reflecting an established, recognised association rather than anecdotal reports.

Experiencing these side effects? Our pharmacists can help you navigate them →

Anastrozole is an aromatase inhibitor widely prescribed in the UK for hormone receptor-positive breast cancer, typically in postmenopausal women. It works by blocking the enzyme aromatase, which is responsible for converting androgens into oestrogen in peripheral tissues. By significantly reducing circulating oestrogen levels — typically by more than 80%, according to the MHRA-approved Summary of Product Characteristics (SmPC) for anastrozole — it helps slow or prevent the growth of oestrogen-dependent tumours.

Because oestrogen plays a role in maintaining the normal hair growth cycle, its suppression can, in some individuals, contribute to hair thinning or hair loss. This type of hair loss is generally described as diffuse thinning rather than the patchy or complete hair loss associated with chemotherapy. It may present as telogen effluvium (a shedding of resting hairs) or in a pattern resembling female pattern hair loss, where hair becomes finer and less dense across the scalp. These patterns are clinically plausible given the hormonal mechanism, though individual presentations vary.

The SmPC for anastrozole, as approved by the Medicines and Healthcare products Regulatory Agency (MHRA), lists alopecia as a known side effect classified as 'common' (affecting between 1 in 100 and 1 in 10 people). This means there is an established, recognised association between anastrozole use and hair loss — it is not merely anecdotal. However, not everyone who takes anastrozole will experience this side effect, and for many patients, the benefits of the medication in reducing cancer recurrence substantially outweigh the risks of hair thinning.

If you experience hair loss or any other side effect whilst taking anastrozole, you can report it to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. Reporting helps the MHRA monitor the safety of medicines in real-world use.

Not sure if this is normal? Chat with one of our pharmacists →

How Common Is Hair Thinning Among Anastrozole Users

Alopecia affects an estimated 1 in 100 to 1 in 10 anastrozole users according to the MHRA-approved SmPC, though patient-reported rates in surveys tend to be higher than those recorded in clinical trials.

According to the MHRA-approved SmPC for anastrozole, alopecia is classified as a 'common' adverse effect, meaning it is estimated to affect between 1 in 100 and 1 in 10 people taking the medicine. This classification is based on data from clinical trials and post-marketing surveillance, and provides the most reliable guide to frequency for UK patients.

In large-scale trials such as the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial — one of the pivotal studies supporting anastrozole's use in early breast cancer — alopecia was reported as an adverse event, though it was not among the most frequently cited side effects. Distinguishing anastrozole-induced hair loss from other causes can be challenging in this population. Many patients receiving anastrozole have previously undergone chemotherapy, which itself causes significant hair loss. Post-chemotherapy hair regrowth can sometimes be incomplete or altered in texture, making it difficult to attribute ongoing thinning solely to anastrozole. Natural age-related hair thinning and stress-related effluvium may also coincide with the period during which anastrozole is prescribed.

Self-reported rates of hair thinning in patient surveys and observational studies tend to be higher than those recorded in randomised controlled trials, suggesting that mild-to-moderate hair changes may be under-reported in formal clinical settings. Research published in the journal Breast Cancer Research and Treatment has highlighted that patient-reported outcomes often capture a broader picture of quality-of-life impacts — including hair changes — than clinician-recorded adverse events alone. This discrepancy underscores the importance of open communication between patients and their oncology teams about all symptoms experienced during treatment.

Managing Hair Loss While Taking Anastrozole

Gentle hair care, nutritional screening, and discussion of off-label topical minoxidil with your clinical team are the main management options; never stop anastrozole without consulting your oncologist.

If you notice hair thinning whilst taking anastrozole, there are several practical steps that may help minimise its impact and support scalp health during treatment:

• Gentle hair care: Use mild, sulphate-free shampoos and avoid excessive heat styling, tight hairstyles, or harsh chemical treatments that can further stress fragile hair.

• Nutritional support: Ensure adequate intake of nutrients important for hair health, including iron and protein. Deficiencies in iron, vitamin D, or vitamin B12 are relatively common and can independently contribute to hair loss. Your GP can arrange blood tests to check relevant levels based on your individual history and symptoms.

• Minoxidil: This topical treatment is available over the counter in the UK and is licensed for androgenetic alopecia (female pattern hair loss). Its use for aromatase inhibitor-related hair thinning is off-label, meaning it has not been specifically licensed for this indication, and the evidence base in this context is limited. It is important to discuss this option with your GP, oncologist, or dermatologist before starting, particularly during cancer treatment.

• Scalp massage: Some limited, low-quality evidence suggests that regular gentle scalp massage may modestly support hair density by increasing blood flow to follicles. However, the evidence is not robust, and this should be considered a complementary measure only — it does not replace medical advice or treatment.

It is also important to maintain realistic expectations. Hair thinning associated with anastrozole may improve after stopping the medication in some individuals, though outcomes vary and this is not guaranteed. Any decision to discontinue or alter anastrozole must always be made in close consultation with your oncologist, as doing so may significantly affect your cancer management. Do not stop taking anastrozole without first speaking to your oncology team. Your team can help you weigh the risks and benefits and explore whether any adjustments to your treatment plan are appropriate.

For further information on managing hair loss, the British Association of Dermatologists (BAD) and the NHS hair loss page (nhs.uk) provide evidence-based patient guidance.

When to Speak to Your GP or Oncology Team

Seek prompt advice if hair loss is sudden, patchy, or accompanied by scalp symptoms, as these may indicate a separate condition such as thyroid dysfunction or alopecia areata requiring investigation.

Whilst mild hair thinning during anastrozole treatment may not require urgent medical attention, there are certain circumstances in which you should seek professional advice promptly. It is always appropriate to raise concerns about hair loss at your next scheduled appointment, but some situations warrant earlier contact:

• Sudden or rapid hair loss that occurs over a short period, as this may suggest a cause other than anastrozole, such as thyroid dysfunction or iron deficiency anaemia.

• Patchy hair loss or bald spots, which could indicate alopecia areata — an autoimmune condition unrelated to anastrozole — requiring separate investigation and management.

• Significant psychological distress related to hair changes, as this can affect quality of life and adherence to treatment. NHS psychological support services and cancer charities can provide valuable assistance.

• Scalp symptoms such as itching, scaling, redness, or pain, which may indicate a dermatological condition requiring treatment.

Your GP can arrange relevant blood tests to help rule out other contributory causes of hair loss. Standard investigations in UK primary care typically include thyroid function tests (TSH), a full blood count (FBC), and ferritin. Depending on your clinical history and examination findings, your GP may also consider checking vitamin D, vitamin B12, folate, or other tests such as a coeliac screen. Routine testing for zinc or serum protein is not standard practice and would only be considered in specific clinical circumstances.

If a dermatological cause is suspected, referral to a dermatologist via the NHS may be appropriate. NICE Clinical Knowledge Summaries (CKS) provide guidance for GPs on the assessment and management of hair loss, including female pattern hair loss and alopecia areata. Your oncology team should always be kept informed of any new or worsening symptoms, as they are best placed to assess whether your current treatment regimen remains the most suitable option for your individual circumstances.

Alternatives and Support Options Available on the NHS

Alternative endocrine therapies such as letrozole, exemestane, or tamoxifen may be considered, but any switch must be made collaboratively with your oncologist; NHS wig services and cancer charities also provide practical support.

If hair loss is significantly affecting your quality of life, it is worth discussing with your oncology team whether alternative hormonal therapies might be appropriate. Other aromatase inhibitors, such as letrozole or exemestane, are sometimes considered, though they share a similar mechanism of action and may carry comparable risks of hair thinning. Tamoxifen, a selective oestrogen receptor modulator (SERM), is another option for some patients and has a different side-effect profile; however, it is not suitable for everyone and carries its own risks, including an increased risk of endometrial cancer and thromboembolic events. NICE guidance (NG101: Early and locally advanced breast cancer: diagnosis and management) provides recommendations on the selection of endocrine therapies based on individual patient and tumour characteristics.

Any decision to switch medications must be made collaboratively with your oncologist, taking into account your individual cancer characteristics, menopausal status, and overall health. It is never advisable to change or stop hormonal therapy independently.

In terms of support, the NHS and associated charities offer a range of resources:

• Macmillan Cancer Support provides guidance on managing the physical and emotional effects of cancer treatment, including hair loss (macmillan.org.uk).

• Breast Cancer Now offers a helpline and online forums where patients can share experiences and access peer support (breastcancernow.org).

• NHS wig services: Patients undergoing cancer treatment may be eligible for a wig through the NHS. Provision, eligibility criteria, and any charges vary across the four UK nations and between individual NHS trusts. Speak to your breast care nurse or oncology team about your eligibility and how to access this support locally. Further information is available on the NHS 'Wigs and fabric supports' page (nhs.uk).

• Psychological support: Referral to an NHS clinical psychologist or counsellor may be available if hair loss is contributing to anxiety or low mood.

Remember, you are not alone in experiencing these concerns, and a range of professional and community support is available to help you through your treatment journey.

Frequently Asked Questions